Large Biopharma Company Engages LexaGene in Statement of Work to Expedite Technology Validation
October 20, 2022 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Receives Signed Quote from Large Biopharma Company to Purchase a MiQLab System
October 13, 2022 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Announces MiQLab® System Sale to Veterinary Hospital in California
September 01, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Verifies CDC Monkeypox Assay Works on MiQLab System and Readies Company Should an EUA be Declared
August 29, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 minutes using Isothermal Chemistry
August 24, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
University of Pennsylvania’s School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene’s MiQLab System
August 17, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), an innovative, molecular diagnostics company that has...
LexaGene Reduces Time-to-Result by ~35%
August 10, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Announces Filing of Financial Statements, Revocation of MCTO & the Granting of Incentive Equity Awards to Employees
July 29, 2022 07:58 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Completes Multi-Center Validation Study Using MiQLab® System for Diagnosing Urinary Tract Infections
July 27, 2022 07:58 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...
LexaGene Provides MCTO Update
July 12, 2022 08:00 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized the...